Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Jul 1;25(23):6899–6908. doi: 10.1158/1078-0432.CCR-19-0823

Figure 1.

Figure 1.

Forms of innate and acquired resistance to anti-EGFR agents in metastatic colorectal cancer. (+) denotes the presence of a resistance mechanism (either innate or acquired). (–) denotes the absence of a resistance mechanism (either innate or acquired).